Investigation of the use of serum FGF-23 as an indicator of early diyabetci nephropathy in patients with type 2 diabetes

Diabetes mellitus (DM) is a fatal metabolic disorder The prevalence of this disease has significantly increased in the past couple of decades. It is caused by the continuous increase in the severity and incidence of the disease. Despite the increasing prevalence of diabetes, the number of people with diabetic kidney disease (DKD) has not decreased over the past 30 years. One of the key factors contributing to a shorter lifetime among diabetics is this illness. to determine those who are most at risk of contracting this illness. This study aims To investigate the use of serum FGF-23 as an indicator of early diabetic nephropathy in patients with type 2 diabetes mellitus. 150 participants in all were chosen from those participating at 4 significant clinical laboratories. 100 individuals with type 2 diabetes mellitus were included in the patient group, 50 of them had microalbuminuria and the remaining 50 did not. The average patient age was (minimum=45,maximum=75) year and another 50 participants were healthy once for control. the patients used to attend Al-Yarmouk hospital and Al-Numaan hospital the samples of the patient has been collected from 5th April to 20th august of 2022 all the participants were assessed for whole blood (CBC,hba1c) and serum glucose, renal function test, and liver function test, FGF-23 and ACR (albumin creatinine ratio in urine). The SPSS program version 23 was used to statistically analyze the results. The present study's findings showed a significant difference in the mean serum FGF-23 levels across the groups during investigation. In all groups examined, there was a connection between ACR and serum FGF-23 levels. FGF-23 can be used as an alternative to ACR as an indicator of early diabetic nephropathy. FGF-23 can be useful as an indicator of the progression of diabetic nephropathy.